Table 1. Patients characteristic.
Case no. | Subsite | TNM | Age (yr) | Gender | |
1 | T | Oropharynx | T4aN0M0 | 53 | M |
2 | T | Oropharynx | T4aN2cM0 | 62 | M |
3 | T | Hypopharynx | T3N2bM0 | 83 | M |
4 | T | Hypopharynx | T4aN2cM0 | 62 | F |
5 | T | Oropharynx | T4aN1M0 | 62 | M |
6 | T | Oropharynx | T4aN2cM0 | 54 | M |
7 | T | Hypopharynx | T4aN2cM0 | 63 | M |
8 | T | Oropharynx | T3N2cM0 | 73 | M |
9 | P | Hypopharynx | T4aN2cM0 | 58 | M |
10 | P | Oropharynx | T4aN2cM0 | 64 | M |
11 | P | Larynx | T2N0M0 | 72 | M |
12 | P | Hypopharynx | T4aN2cM0 | 52 | M |
13 | P | Hypopharynx | T2N2cM0 | 49 | M |
14 | P | Maxillary sinus | T3N0M0 | 65 | F |
15 | P | Maxillary sinus | T4aN0M0 | 79 | M |
16 | P | Oropharynx | T3N3M0 | 67 | M |
TNM staging system is defined by Union for International Cancer Control classification system. F, female; M, male; P, placebo;T, TJ-14; yr, years.